In a guest blog for EFPIA (European Federation of Pharmaceutical Industries and Associations), Children’s Tumor Foundation President Annette Bakker writes that a key lesson from the all-out effort to develop covid vaccines has been the effectiveness of platform trials, whereby multiple drugs are tested simultaneously in order to quickly learn which work best. Read more about this promising innovation, including the Children’s Tumor Foundation’s INTUITT-NF2 multi-site platform trial that together with Takeda is evaluating treatments for multiple tumor manifestations for neurofibromatosis type-2 (NF2). In this timely piece, Dr. Bakker also discusses platform trial development for NF within EU-PEARL (EU Patient-Centric Clinical Trial Platforms) of the IMI (Innovative Medicines Initiative), and the critical importance of patient access to treatments, which is being addressed by BRIDGE, a partnership between FasterCures, CureSearch, and the Children’s Tumor Foundation.
Read the Blog Post on the EFPIA website here.
